课题基金 / 基金详情

Curcumin Treatment of Fibrosis

Curcumin Treatment of Fibrosis
姜黄素治疗纤维化
批准号:
6371149
负责人:
STANLEY R HOFFMAN
金额:
$17.88万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-12 至 2003-06-30

项目摘要

项目成果

STANLEY R HOFFMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Practitioners of alternative medicine recommend curcumin, a component of the spice turmeric, as a treatment for autoimmune diseases. Scleroderma is a debilitating autoimmune disease that affects over 100,000 people in the US, mostly women. The hallmark of scleroderma is dermal fibrosis. When accompanied by visceral organ fibrosis, significant morbidity and mortality results. Despite its widespread occurrence, little is known to suggest effective treatment. As part of our long-term objective of understanding the aberrant regulation of extracellular matrix protein accumulation in scleroderma, we treated primary fibroblast cultures from the lungs of scleroderma patients with curcumin. We found that this treatment inhibits collagen accumulation and promotes cell death in these cultures while having no effect on normal lung fibroblasts. Interestingly, these effects of curcumin on scleroderma fibroblasts are enhanced in the presence of vitamin C. If curcumin were to have the same effect on scleroderma fibroblasts in vivo as it has in culture, then curcumin would be likely to be an effective treatment for scleroderma. While curcumin is not yet used in standard medical practice, in Chinese and Indian folk medicine turmeric is used to treat a broad range of ailments. Published articles show curcumin to have a range of potent biological activities including anticancer, anti-inflammatory, and antimicrobial. The use of curcumin in folk medicine, published studies on curcumin, and our results combine to indicate that curcumin is non-toxic and is a treatment already used in alternative medicine that is likely to have demonstrably positive effects on patients with scleroderma and other fibrotic diseases. In order to test the hypothesis that curcumin may be a beneficial treatment for scleroderma in particular and fibrotic diseases in general, we will: 1) Use cultured fibroblasts to determine the molecular and cellular mechanisms involved in the specific effects of curcumin on cells from scleroderma patients and 2) We will perform translational research using an animal model for scleroderma and lung fibrosis to determine whether curcumin is indeed effective in treating lung fibrosis in vivo. These experiments will demonstrate the efficacy and the scientific basis for that efficacy of a disease treatment already recommended by practitioners of alternative medicine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development
  • 批准号:
    10599654
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2023
  • 负责人:
    STANLEY R HOFFMAN
  • 依托单位:
Development of Modified Caveolin-1 Scaffolding Domain Peptides with Improved Pharmacological Properties as Therapeutic Agents for Scleroderma Skin Disease
  • 批准号:
    10544238
  • 项目类别:
  • 资助金额:
    $25.96万
  • 财政年份:
    2022
  • 负责人:
    STANLEY R HOFFMAN
  • 依托单位:
Novel Therapeutics for Interstitial Lung Disease: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development
  • 批准号:
    10544228
  • 项目类别:
  • 资助金额:
    $29.99万
  • 财政年份:
    2022
  • 负责人:
    STANLEY R HOFFMAN
  • 依托单位:
Curcumin Treatment of Lung Fibrosis: Improved Delivery and Target Cells
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: